Price history
Select outcomes to plot.
Description
FDA approves GSK & Spero Therapeutics' Tebipenem HBr? is a June 18, 2026 decision window market on cUTI and pyelonephritis treatment. The Yes outcome requires FDA granting full or conditional approval by July 2, 2026, 11:59 PM ET under NDA, sNDA, ANDA, or 351(k) routes as applicable, with approval considered if an official letter or equivalent authorization is issued. If a CRL is issued, or the sponsor withdraws, the market resolves to No. Resolution relies on official FDA information or a credible reporting consensus when needed.
Event stats
24h volume
Total volume
Liquidity
Markets
1
Market highlights
Top market
24h gainer
24h loser
Highest volume
Top market
24h gainer
24h loser
Highest volume
Related events
FDA approves Unicycive's Oxylanthanum carbonate?Largest IPO by market cap in 2026?FDA approves Arcalyst technology transfer?FDA approves Viridian Therapeutics' Veligrotug?FDA approves Ionis' Olezarsen?FDA approves Arcutis' Zoryve cream?Will SpaceX or OpenAI IPO first?FDA approves Camurus' Oclaiz?FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?Tesla and xAI merger officially announced by June 30?
Markets
Outcome | Odds | Spread | 24h Change | 24h Volume | Total Volume | Liquidity | |
|---|---|---|---|---|---|---|---|
| FDA approves GSK & Spero Therapeutics' Tebipenem HBr? | Yes | — | — | — | — | — |
Rules
As of market creation, the FDA's expected decision date for the specified application is June 18, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for GSK & Spero Therapeutics's Tebipenem HBr as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis by July 2, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.